. 2023 Mar 14;11(1):50. doi: 10.3390/diseases11010050

Table 3.

Changes of BMI and HbA1c from the baseline in type 2 diabetes mellitus subjects treated with GLP-1RAs.

	n	Baseline	Month 6	The Difference at Month 6	p-Value
	n	Baseline	Month 6	The Difference at Month 6	Baseline vs. 6 Months ^a	Between Groups, Statins vs. No Statins ^b
BMI(kg\m²)						0.449
Statin	59	37.3 ± 0.84	35.63 ± 0.8	−1.68 ± 0.4	<0.001
No Statin	7	36.04 ± 3.23	35.26 ± 3.07	−0.78 ± 0.58	0.228
HbA1c (%)						0.736
Statin	53	9.24 ± 0.27	7.94 ± 0.24	−1.3 ± 0.24	<0.001
No Statin	7	6.94 ± 0.79	5.87 ± 0.44	−1.07 ± 0.39	0.032

BMI: body mass index, HbA1c: hemoglobin A1c, ^a paired test, ^b independent t-test. Bold and underlined values indicate statistical significance.